News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘GynecologicCancers’ clear

  • Researchers from the Susan F. Smith Center for Women’s Cancers at Dana-Farber report that for some women with recurrent ovarian cancer, a new drug combination has been found to stall the progression of the disease.

Tags: OvarianCancer, GynecologicCancers

  • Dana-Farber researchers have received a three-year, $1.2 million research grant from Stand Up To Cancer (SU2C) and the Farrah Fawcett Foundation to lead a team in developing and testing new vaccines for patients with cancers linked to the human papillomavirus (HPV).

Tags: Grants, HeadNeckCancers, GynecologicCancers

  • Ursula Matulonis, MD, the director of the Gynecological Cancer Treatment Center in the Susan F. Smith Center for Women’s Cancers at Dana-Farber receives a $900,000 grant from the Ovarian Cancer Research Foundation (OCRF) to test new combinations of targeted drugs against the disease.

Tags: Grants, OvarianCancer, GynecologicCancers

  • Dana-Farber scientists identify a genetic flaw that drives some ovarian cancers, which could assist in identifying treatments for ovarian cancer patients.

Tags: Genomics, OvarianCancer, GynecologicCancers

  • Ursula Matulonis, MD, director of the Gynecologic Oncology Program in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, says there are three things that every woman should know about ovarian cancer — known as the silent killer.

Tags: OvarianCancer, GynecologicCancers

  • A first of its kind study has revealed marked differences in the genomic terrain of the two most common types of cervical cancer, suggesting that patients might benefit from targeted therapies for each type’s molecular idiosyncrasies.

Tags: CervicalCancer, Genomics, GynecologicCancers

  • A novel pairing of two cancer drug types showed promising activity and had manageable toxicities, according to a first-of-its-kind clinical trial led by scientists at Dana-Farber Cancer Institute.

Tags: BreastCancer, OvarianCancer, GynecologicCancers

  • Dana-Farber scientists find when given together, two orally available experimental drugs – sapacitabine and seliciclib – worked together to elicit antitumor effects in patients with incurable BRCA-deficient cancers.

Tags: BasicResearch, BreastCancer, PancreaticCancer, GynecologicCancers

  • Dana-Farber researchers find novel antibody-guided drug achieves responses in platinum drug-resistant ovarian cancer.

Tags: OvarianCancer, GynecologicCancers

  • A new study that proposes a three-in-one test for gynecologic cancers underscores the promise of molecular screening for early detection of endometrial and ovarian cancers, but also suggests that such tests are not yet ready for clinical use. Andrea Myers, MD, PhD, a co-author of the commentary on the study, says the test is an important step in that direction.

Tags: CervicalCancer, OvarianCancer, Prevention, GynecologicCancers

Showing 1-10 of 19 items